Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome

B. L. Moskovitz, H. C. Lane, H. Masur, M. Lange, A. Englard, G. McKinley, P. A. Volberding, D. Abrams, D. Mildvan, M. Gottlieb, P. Wolfe, B. F. Polk, D. Druckman, B. Poiesz, C. R. Smith, J. E. Kusmierek, K. E. Smith

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Abstract

An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-tungsto-9-antimoniate) in patients with acquired immune deficiency syndrome. Sixty-nine patients were sequentially assigned to receive 0.25, 0.5, 1.0, or 2.0 mg of HPA-23 per kg intravenously 5 days per week for 8 weeks. HPA-23 was fairly well tolerated at doses of 1.0 mg/kg or less; nearly 60% of patients given 2.0 mg/kg discontinued treatment. Twenty-six patients discontinued treatment because of adverse events or concurrent illness. HPA-23 produced dose-related decreases in platelet count and increases in serum glutamine oxalacetic transaminase. There were no changes in immune system function, as determined by total lymphocyte count, T4-cell count, T8-cell count, and T4/T8 ratio. The effects of HPA-23 seemed to be more closely related to the total dose than to the daily dose. No improvement in the clinical status of the patients was observed during the 8 weeks of treatment.

Original languageEnglish
Pages (from-to)1300-1303
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume32
Issue number9
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome'. Together they form a unique fingerprint.

Cite this